These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11583176)

  • 1. Are european cancer patients getting a fair deal?
    McVie JG
    Ann Oncol; 2001 Aug; 12(8):1033-5. PubMed ID: 11583176
    [No Abstract]   [Full Text] [Related]  

  • 2. While We're at It, Let's Whack the FDA.
    Chabner BA
    Oncologist; 2016 Mar; 21(3):259-60. PubMed ID: 26869585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.
    Shah RR; Roberts SA; Shah DR
    Br J Clin Pharmacol; 2013 Sep; 76(3):396-411. PubMed ID: 23362829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-agnostic cancer drug pipeline grows, despite doubts.
    Garber K
    Nat Rev Drug Discov; 2018 Apr; 17(4):227-229. PubMed ID: 29520093
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 6. US Food and Drug Administration approves first cancer treatment for any solid tumors with specific biomarker.
    Cancer; 2017 Oct; 123(19):3652-3653. PubMed ID: 28940329
    [No Abstract]   [Full Text] [Related]  

  • 7. Early accelerated approval for highly targeted cancer drugs.
    Chabner BA
    N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
    Amiri-Kordestani L; Pazdur R
    Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Swimming upstream: an advocate reflects on cancer research and social realities.
    Mayer M
    J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190
    [No Abstract]   [Full Text] [Related]  

  • 10. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 11. Perspective: protect the USA from UVA.
    Werner MJ
    Nature; 2014 Nov; 515(7527):S126. PubMed ID: 25407712
    [No Abstract]   [Full Text] [Related]  

  • 12. Beyond fast track for drug approvals.
    Roberts TG; Chabner BA
    N Engl J Med; 2004 Jul; 351(5):501-5. PubMed ID: 15282359
    [No Abstract]   [Full Text] [Related]  

  • 13. Global logistics hamper international oncology trials.
    Senior K
    Lancet Oncol; 2013 Mar; 14(3):193. PubMed ID: 23580956
    [No Abstract]   [Full Text] [Related]  

  • 14. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
    Goozner M
    J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
    [No Abstract]   [Full Text] [Related]  

  • 15. The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another.
    Tao D; Schott S; Prasad V
    Am J Med; 2019 Mar; 132(3):e509-e511. PubMed ID: 30201241
    [No Abstract]   [Full Text] [Related]  

  • 16. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials.
    Tibau A; Molto C; Borrell M; Del Paggio JC; Barnadas A; Booth CM; Amir E
    JAMA Oncol; 2018 Nov; 4(11):1610-1611. PubMed ID: 30267037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expediting the availability of drugs for US patients with cancer.
    Farrell AT; Pazdur R; von Eschenbach AC
    Nat Clin Pract Urol; 2008 Dec; 5(12):654-6. PubMed ID: 19050708
    [No Abstract]   [Full Text] [Related]  

  • 18. Difficult decisions.
    Nat Med; 2011 Aug; 17(8):901. PubMed ID: 21818065
    [No Abstract]   [Full Text] [Related]  

  • 19. Oncology drugs enter the US market faster than in Europe but cost more.
    Mitka M
    JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
    [No Abstract]   [Full Text] [Related]  

  • 20. Paying for Cancer Drugs That Prove Their Benefit.
    Frank RG; Emanuel EJ
    JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.